Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

quote:

braber schreef op 29 april 2020 15:11:

GILEAD! REMDESIVIR WERKT TÓCH?
14:40
(AJK) Duimen voor dat middel van Gilead, er zijn toch goede resultaten. Daar werd dit weekend nog aan getwijfeld. Het middel Remdesivir gaat door voor de volgende testronde. de koers wellicht ook. We zien het straks wel. We mogen in ieder geval weer even hopen.

quote:

Zonder dollen schreef op 29 april 2020 15:53:

[...]

Volgens mij moet er nog getest worden of Ruconest IC opname kan voorkomen. Iets met 150 personen of zo?

quote:

s.lin schreef op 29 april 2020 16:11:

New Capricor Data Reports 100 Percent Survival in Critical COVID-19 Patients Treated with CAP-1002
April 29, 2020
LOS ANGELES, April 29, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment and prevention of diseases, announced today new data reporting 100 percent survival in critical COVID-19 patients who were treated with Capricor’s lead asset, off-the-shelf (“allogeneic”) cardiac cell therapy CAP-1002, at Cedars-Sinai Medical Center as part of six compassionate care cases.

Over the course of one month, six critically ill COVID-19 patients, all suffering from acute respiratory distress syndrome (ARDS) and five of whom were on mechanical ventilatory support, were safely treated with CAP-1002. Of the six patients treated, four of them have been discharged. Following a review of the available data, the U.S. Food and Drug Administration (FDA) approved the Company’s expanded access protocol to treat up to 20 additional COVID-19 patients. There is also a randomized, placebo-controlled trial planned to treat patients with moderate and severe disease which is intended to be funded by non-equity capital.

In the compassionate care cases, five male patients and one female patient (between ages 19 and 75) suffering from COVID-19 received IV infusions of 150 million allogeneic cardiosphere-derived cells (CAP-1002). Of the five patients on ventilator support, four patients no longer required ventilator support within just one to four days following the infusion. The fifth patient remains on mechanical ventilation and the sixth patient is receiving supplemental oxygen and is currently clinically stable. Additionally, laboratory biomarkers correlated with poor outcomes were measured in all patients. Following infusion, several patients showed improvements in biomarkers, such as ferritin, absolute lymphocyte counts and CRP. No adverse events related to the administration of CAP-1002 were observed. This data has been submitted for publication.

CAP-1002 demonstrates immunomodulatory properties. Multiple published peer-reviewed studies of CDCs have demonstrated favorable modulation of various inflammatory cytokines and regulation of the immune response. The current understanding of COVID-19’s later stages are thought to be due to overstimulation of the immune system, which triggers a cytokine storm in which the body is overwhelmed with pro-inflammatory molecules. This immune response may become excessive and pathologic, inducing pneumonia, organ failure and death. Therefore, it can be the body's overreaction to COVID-19, rather than the virus itself, that delivers the fatal blow.

"As the global medical community continues to come together in its battle against COVID-19, the results of our initial compassionate care cases are extremely promising and what we had anticipated. We look forward to continuing to treat additional patients under our recently approved expanded access program Investigational New Drug application,” said Dr. Linda Marbán, Ph.D., CEO, Capricor. “CAP-1002 is an easy-to-deliver intravenous therapy that has been administered successfully to over 150 patients to date. Given its novel mechanism of action, it could be a potential game-changer in helping countless COVID-19 patients.”

Capricor is also in late-stage clinical development of CAP-1002 for Duchenne muscular dystrophy (DMD). In DMD, the lack of dystrophin produces abnormal inflammatory responses, which are responsible for much of the damage to skeletal and cardiac muscle. The Company has previously announced that top-line results of HOPE-2, a randomized, placebo-controlled study, will be released by mid-May 2020.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment and prevention of diseases. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor is also investigating the field of extracellular vesicles and exploring the potential of exosome-based candidates to treat or prevent a variety of disorders. For more information, visit www.capricor.com and follow the Company on Facebook, Instagram and Twitter.

About CAP-1002

CAP-1002 consists of allogeneic “off-the-shelf” cardiosphere-derived cells, or CDCs, a type of cardiac cell therapy that has been shown in pre-clinical and clinical studies to exert potent immunomodulatory activity. It is being investigated for its potential to modify the immune system’s activity to encourage cellular regeneration. The cells function by releasing exosomes that are taken up largely by macrophages and T-cells and begin a cycle of repair. CDCs have been the subject of over 100 peer-

irdirect.net/prviewer/release/id/4306152

quote:

Reply schreef op 29 april 2020 16:13:

Ook Nico Bakker wordt vanuit zijn TA nu reeds positiever.
Momenteel lijkt de beurs sowieso ook elk nieuwsbericht positief op te pakken, negatief of niet, het moet en zal blijkbaar omhoog?!

Nico PR Bakker/BNPP Markets NL
PHARMING kan zijn pulllback afronden boven de 1e Fibostreep op 1,20, weg omhoog naar 1,40 tot 1,50 wordt langzaamaan ingezet.... t.co/q2aPdvKWfi

quote:

B.enieuwd schreef op 29 april 2020 16:15:

[...]

Stijging op dit moment van 120%!

quote:

Ron61 schreef op 29 april 2020 16:26:

En dan gaat het hier over:

Gedurende een maand werden zes ernstig zieke COVID-19-patiënten, allemaal met acute respiratory distress syndrome (ARDS) en vijf van hen die mechanische beademingsondersteuning kregen, veilig behandeld met CAP-1002. Van de zes behandelde patiënten zijn er vier ontslagen.

quote:

Wuhatsjoe schreef op 29 april 2020 16:29:

[...]

De PR trommels van Pharming hebben onvoldoende hard geroffeld.
Pharming moet nu echt vaart gaan maken, anders is hun kans verkeken.

quote:

s.lin schreef op 29 april 2020 16:31:

Pharming loopt nu misschien achter de feiten aan